(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a second tranche of a private placement financing for gross proceeds of CAD510,000. The Company is working on completing another private placement financing tranche by May 17, 2019.
20190429-HBP-Press-Release-Closes-Private-Placement-Tranche2.pdf